Research Studies

We are recruiting participants to test a virtual program dedicated to supporting the wellbeing of young adults with T1D. Participants will either receive 8-10 coaching sessions with a health coach or educational emails to help support their diabetes management, communication with their support system, and overall wellbeing. Participation in the program will help us evaluate its effectiveness and make any necessary improvements to better support young adults with T1D. Compensation is provided.

The purpose of this study is to explore experiences with virtual care. We are asking people that have gestational diabetes (GDM) to share their thoughts and experience in a focus group. We are recruiting individuals who pregnancy received care in Alberta. The study results will help us determine if there are differences between in-person and virtual care for GDM management, informing us how to improve GDM care in the future.

This study compares aerobic exercise training performed before breakfast (i.e., in the fasted state) to similar training performed after breakfast in people with type 1 diabetes. Training will take place over 12 weeks in the Physical Activity Diabetes Lab at the Alberta Diabetes Institute.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of an investigational islet cell infusion in individuals aged 18 to 65 with type 1 diabetes with severe low blood sugar (hypoglycemia) and impaired hypoglycemic awareness. The goal of this infusion is to provide replacement cells for the ones that have been lost or do not work properly in people with diabetes. For more information, please respond to this ad and the study team will reach out to you.

Contemporary treatment of types 2 diabetes regularly involves the use of SGLT2 inhibitors. There is now interest in using this medication for type 1 diabetes alongside insulin treatment. T1D patient input is critical in understanding how and when the use of SGLT2 inhibitors is considered acceptable. We wish to explore the thoughts and perspectives of T1D patients about all the factors they would need to consider before starting this medication, including any risks or benefits they anticipate.

Gender shapes health experiences and care needs, yet little is known about how gender roles and identities impact experiences with T1D. This qualitative study uses photography to explore the relationships between gender, self-management, and care for emerging adults (18-29 years of age) with Type 1 Diabetes. Individuals are asked to take part in a virtual focus group, followed by a photo taking exercise (capturing between 5-25 images), and one-on-one interview to discuss photographs taken.

The purpose of this study is to evaluate the effectiveness of 2.5mg empagliflozin (Jardiance) in improving glucose control in people living with type 1 diabetes using an insulin pump. We’re recruiting adults with type 1 diabetes using an advanced automated insulin pump (ex: Medtronic 780G, Tandem t:slim, etc.) with a sub-optimal glycemic outcomes (TIR below 70%). The study will last between 6-7 months and includes 3 visits of about 60-90mins.

Inequities in T1D care present barriers to achieving equitable health outcomes for individuals with T1D. One contributor to disparities in diabetes care outcomes is the unequal utilization of advanced diabetes technologies like insulin pump, CGM, and closed loop. This study aims to determine enablers and barriers to initiation of advanced diabetes technologies among socially disadvantaged individuals with T1D. Individuals are asked to share their experiences through a semi-structured interview.

Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing type 1 diabetes (T1D). This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Screening is offered to family members of people with T1D.